Cargando…
Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review
Inflammatory bowel disease (IBD) is a general term used to describe a group of chronic inflammatory conditions of the gastrointestinal tract of unknown etiology, including two primary forms: Crohn’s disease (CD) and ulcerative colitis (UC). The endocannabinoid system (ECS) plays an important role in...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727741/ https://www.ncbi.nlm.nih.gov/pubmed/35003109 http://dx.doi.org/10.3389/fimmu.2021.790803 |
_version_ | 1784626585806045184 |
---|---|
author | Hryhorowicz, Szymon Kaczmarek-Ryś, Marta Zielińska, Aleksandra Scott, Rodney J. Słomski, Ryszard Pławski, Andrzej |
author_facet | Hryhorowicz, Szymon Kaczmarek-Ryś, Marta Zielińska, Aleksandra Scott, Rodney J. Słomski, Ryszard Pławski, Andrzej |
author_sort | Hryhorowicz, Szymon |
collection | PubMed |
description | Inflammatory bowel disease (IBD) is a general term used to describe a group of chronic inflammatory conditions of the gastrointestinal tract of unknown etiology, including two primary forms: Crohn’s disease (CD) and ulcerative colitis (UC). The endocannabinoid system (ECS) plays an important role in modulating many physiological processes including intestinal homeostasis, modulation of gastrointestinal motility, visceral sensation, or immunomodulation of inflammation in IBD. It consists of cannabinoid receptors (CB1 and CB2), transporters for cellular uptake of endocannabinoid ligands, endogenous bioactive lipids (Anandamide and 2-arachidonoylglycerol), and the enzymes responsible for their synthesis and degradation (fatty acid amide hydrolase and monoacylglycerol lipase), the manipulation of which through agonists and antagonists of the system, shows a potential therapeutic role for ECS in inflammatory bowel disease. This review summarizes the role of ECS components on intestinal inflammation, suggesting the advantages of cannabinoid-based therapies in inflammatory bowel disease. |
format | Online Article Text |
id | pubmed-8727741 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87277412022-01-06 Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review Hryhorowicz, Szymon Kaczmarek-Ryś, Marta Zielińska, Aleksandra Scott, Rodney J. Słomski, Ryszard Pławski, Andrzej Front Immunol Immunology Inflammatory bowel disease (IBD) is a general term used to describe a group of chronic inflammatory conditions of the gastrointestinal tract of unknown etiology, including two primary forms: Crohn’s disease (CD) and ulcerative colitis (UC). The endocannabinoid system (ECS) plays an important role in modulating many physiological processes including intestinal homeostasis, modulation of gastrointestinal motility, visceral sensation, or immunomodulation of inflammation in IBD. It consists of cannabinoid receptors (CB1 and CB2), transporters for cellular uptake of endocannabinoid ligands, endogenous bioactive lipids (Anandamide and 2-arachidonoylglycerol), and the enzymes responsible for their synthesis and degradation (fatty acid amide hydrolase and monoacylglycerol lipase), the manipulation of which through agonists and antagonists of the system, shows a potential therapeutic role for ECS in inflammatory bowel disease. This review summarizes the role of ECS components on intestinal inflammation, suggesting the advantages of cannabinoid-based therapies in inflammatory bowel disease. Frontiers Media S.A. 2021-12-22 /pmc/articles/PMC8727741/ /pubmed/35003109 http://dx.doi.org/10.3389/fimmu.2021.790803 Text en Copyright © 2021 Hryhorowicz, Kaczmarek-Ryś, Zielińska, Scott, Słomski and Pławski https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Hryhorowicz, Szymon Kaczmarek-Ryś, Marta Zielińska, Aleksandra Scott, Rodney J. Słomski, Ryszard Pławski, Andrzej Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review |
title | Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review |
title_full | Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review |
title_fullStr | Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review |
title_full_unstemmed | Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review |
title_short | Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review |
title_sort | endocannabinoid system as a promising therapeutic target in inflammatory bowel disease – a systematic review |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727741/ https://www.ncbi.nlm.nih.gov/pubmed/35003109 http://dx.doi.org/10.3389/fimmu.2021.790803 |
work_keys_str_mv | AT hryhorowiczszymon endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview AT kaczmarekrysmarta endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview AT zielinskaaleksandra endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview AT scottrodneyj endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview AT słomskiryszard endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview AT pławskiandrzej endocannabinoidsystemasapromisingtherapeutictargetininflammatoryboweldiseaseasystematicreview |